Dapiglutide: Novel GLP-1/GLP-2 Agonist Shows Promise in Early Obesity Trials

A new drug, dapiglutide, combining GLP-1 and GLP-2 receptor activation, is being investigated as a potential treatment for obesity. Early trial results indicate the drug is safe and may promote weight loss, though initial findings haven’t reached statistical significance compared to placebo.

Understanding Obesity and Current Treatments

Obesity is a growing global health concern, affecting millions and contributing to serious conditions like type 2 diabetes, heart disease, stroke, and certain cancers . Traditional weight loss methods, focusing on diet and exercise, often yield limited long-term success, with many individuals experiencing weight regain.

The Rise of GLP-1 Agonists

Recent advancements in obesity treatment have centered around GLP-1 receptor agonists, such as semaglutide, which mimic natural hormones to promote feelings of fullness and reduce food intake. These drugs have demonstrated substantial weight-loss efficacy .

Dapiglutide: A Dual-Receptor Approach

Dapiglutide represents a next-generation approach, acting as a dual GLP-1/GLP-2 receptor agonist. The GLP-1 component aims to reduce appetite, while the GLP-2 component is believed to influence gut health, potentially improving intestinal barrier function and reducing inflammation . The role of GLP-2 in human obesity is still being investigated.

Phase IIa Trial Results

A recent Phase IIa trial, conducted in Denmark, evaluated the safety and efficacy of dapiglutide in 54 adults with obesity. Participants were randomized to receive either 4 mg or 6 mg of dapiglutide weekly, or a placebo, for 12 weeks .

• Weight Loss: The 6 mg dapiglutide group experienced a 2.1% greater reduction in body weight compared to the placebo group (p = 0.076). While this suggests a potential benefit, it did not reach statistical significance.
• Placebo Effect: Notably, the placebo group itself experienced an average weight loss of 2.2%, highlighting the impact of lifestyle factors and participant expectations.
• Glycemic Control: Participants receiving 6 mg of dapiglutide showed a 2.4 mmol/mol reduction in HbA1c (a marker of long-term blood sugar control) compared to a 0.1 mmol/mol reduction in the placebo group (p = 0.006).
• Safety and Tolerability: Dapiglutide was generally well-tolerated, with the most common side effects being gastrointestinal, including reduced appetite and nausea. No participants discontinued the trial due to adverse events.

Looking Ahead

Although the initial trial did not demonstrate statistically significant weight loss compared to placebo, the findings suggest dapiglutide is safe and may offer metabolic benefits. Further research, including larger trials with higher doses and longer treatment durations, is needed to fully evaluate the potential of this dual-receptor agonist in the treatment of obesity .